Journal of Endocrinological Investigation

, Volume 42, Issue 1, pp 27–35 | Cite as

Effects of growth hormone on pregnancy rates of patients with thin endometrium

  • N. Cui
  • A.-M. Li
  • Z.-Y. Luo
  • Z.-M. Zhao
  • Y.-M. Xu
  • J. Zhang
  • A.-M. Yang
  • L.-L. Wang
  • G.-M. HaoEmail author
  • B.-L. GaoEmail author
Original Article



To investigate whether growth hormone (GH) could improve pregnancy rates of patients with thin endometrium by clinical study and laboratory experiments.

Materials and methods

Ninety-three patients were randomized to either the GH-received group (40) or the routine exogenous administration of estrogens control group (53) for clinical study. The human endometrial carcinoma cell line RL95-2 was used for testing the role of GH with Western blot and real-time PCR by exposure to various concentrations of GH (0.1 nM,1 nM,10 nM,100 nM).


Patients treated with GH had a significantly (P < 0.05) greater endometrium thickness on day 3 (7.87±0.72 vs 6.34±0.86), higher implantation rates (24.4% vs 10.5%) and greater clinical pregnancy rates (42.5% vs 18.9%) compared with the control group. No adverse events were associated with the use of GH. Administration of GH significantly up-regulated the expression of VEGF, ItgB3 and IGF-I expression in RL95-2 cells at both mRNA and protein levels (P < 0.05). AG490, an inhibitor of JAK2, nearly completely inhibited the up-regulative effect of GH through the JAK2-STAT5 pathway, and GH-induced effects could be mediated through autocrine IGF-I together with its hepatic counterpart. IGF-I mRNA was detected in the RL95-2 cells.


GH may improve pregnancy outcomes of patients with thin endometrium who undergo frozen embryo transfer by acting on human endometrial cells to promote proliferation and vascularization and to up-regulate receptivity-related molecular expression.


Endometrial thickness Growth hormone Pregnancy rate Cell experiment Mechanism 



This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.

Compliance with ethical standards

Conflict of interest

We declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.


  1. 1.
    Kunicki M, Lukaszuk K, Woclawek-Potocka I, Liss J, Kulwikowska P, Szczyptanska J (2014) Evaluation of granulocyte colony-stimulating factor effects on treatment-resistant thin endometrium in women undergoing in vitro fertilization. Biomed Res Int 2014:913235CrossRefGoogle Scholar
  2. 2.
    Richter KS, Bugge KR, Bromer JG, Levy MJ (2007) Relationship between endometrial thickness and embryo implantation, based on 1,294 cycles of in vitro fertilization with transfer of two blastocyst-stage embryos. Fertil Steril 87:53–59CrossRefGoogle Scholar
  3. 3.
    Kasius A, Smit JG, Torrance HL, Eijkemans MJ, Mol BW, Opmeer BC, Broekmans FJ (2014) Endometrial thickness and pregnancy rates after IVF: a systematic review and meta-analysis. Hum Reprod Update 20:530–541CrossRefGoogle Scholar
  4. 4.
    Takasaki A, Tamura H, Miwa I, Taketani T, Shimamura K, Sugino N (2010) Endometrial growth and uterine blood flow: a pilot study for improving endometrial thickness in the patients with a thin endometrium. Fertil Steril 93:1851–1858CrossRefGoogle Scholar
  5. 5.
    Ledee-Bataille N, Olivennes F, Lefaix JL, Chaouat G, Frydman R, Delanian S (2002) Combined treatment by pentoxifylline and tocopherol for recipient women with a thin endometrium enrolled in an oocyte donation programme. Hum Reprod 17:1249–1253CrossRefGoogle Scholar
  6. 6.
    Letur-Konirsch H, Delanian S (2003) Successful pregnancies after combined pentoxifylline-tocopherol treatment in women with premature ovarian failure who are resistant to hormone replacement therapy. Fertil Steril 79:439–441CrossRefGoogle Scholar
  7. 7.
    Gleicher N, Kim A, Michaeli T, Lee HJ, Shohat-Tal A, Lazzaroni E, Barad DH (2013) A pilot cohort study of granulocyte colony-stimulating factor in the treatment of unresponsive thin endometrium resistant to standard therapies. Hum Reprod 28:172–177CrossRefGoogle Scholar
  8. 8.
    Xu B, Zhang Q, Hao J, Xu D, Li Y (2015) Two protocols to treat thin endometrium with granulocyte colony-stimulating factor during frozen embryo transfer cycles. Reprod Biomed Online 30:349–358CrossRefGoogle Scholar
  9. 9.
    Carter-Su C, Schwartz J, Argetsinger LS (2016) Growth hormone signaling pathways. Growth Horm IGF Res 28:11–15CrossRefGoogle Scholar
  10. 10.
    Sharara FI, Nieman LK (1995) Growth hormone receptor messenger ribonucleic acid expression in leiomyoma and surrounding myometrium. Am J Obstet Gynecol 173:814–819CrossRefGoogle Scholar
  11. 11.
    Cohen O, Schindel B, Homburg R (1998) Uterine leiomyomata—a feature of acromegaly. Hum Reprod 13:1945–1946CrossRefGoogle Scholar
  12. 12.
    Oliveira CR, Salvatori R, Nobrega LM, Carvalho EO, Menezes M, Farias CT, Britto AV, Pereira RM, Aguiar-Oliveira MH (2008) Sizes of abdominal organs in adults with severe short stature due to severe, untreated, congenital GH deficiency caused by a homozygous mutation in the GHRH receptor gene. Clin Endocrinol (Oxf) 69:153–158CrossRefGoogle Scholar
  13. 13.
    Guevara-Aguirre J, Balasubramanian P, Guevara-Aguirre M, Wei M, Madia F, Cheng CW, Hwang D, Martin-Montalvo A, Saavedra J, Ingles S, de Cabo R, Cohen P, Longo VD (2011) Growth hormone receptor deficiency is associated with a major reduction in pro-aging signaling, cancer, and diabetes in humans. Sci Transl Med 3:70ra13CrossRefGoogle Scholar
  14. 14.
    Slater M, Cooper M, Murphy CR (2006) Human growth hormone and interleukin-6 are up-regulated in endometriosis and endometrioid adenocarcinoma. Acta Histochem 108:13–18CrossRefGoogle Scholar
  15. 15.
    Steuerman R, Shevah O, Laron Z (2011) Congenital IGF1 deficiency tends to confer protection against post-natal development of malignancies. Eur J Endocrinol 164:485–489CrossRefGoogle Scholar
  16. 16.
    Sbracia M, Scarpellini F, Poverini R, Alo PL, Rossi G, Di Tondo U (2004) Immunohistochemical localization of the growth hormone in human endometrium and decidua. Am J Reprod Immunol 51:112–116CrossRefGoogle Scholar
  17. 17.
    Bergh C, Hillensjo T, Wikland M, Nilsson L, Borg G, Hamberger L (1994) Adjuvant growth hormone treatment during in vitro fertilization: a randomized, placebo-controlled study. Fertil Steril 62:113–120CrossRefGoogle Scholar
  18. 18.
    Keane KN, Yovich JL, Hamidi A, Hinchliffe PM, Dhaliwal SS (2017) Single-centre retrospective analysis of growth hormone supplementation in IVF patients classified as poor-prognosis. BMJ Open 7:e018107CrossRefGoogle Scholar
  19. 19.
    Li XL, Wang L, Lv F, Huang XM, Wang LP, Pan Y, Zhang XM (2017) The influence of different growth hormone addition protocols to poor ovarian responders on clinical outcomes in controlled ovary stimulation cycles: a systematic review and meta-analysis. Medicine (Baltimore) 96:e6443CrossRefGoogle Scholar
  20. 20.
    Casper RF (2011) It’s time to pay attention to the endometrium. Fertil Steril 96:519–521CrossRefGoogle Scholar
  21. 21.
    Drakopoulos P, Pluchino N, Bischof P, Cantero P, Meyer P, Chardonnens D (2016) Effect of growth hormone on endometrial thickness and fertility outcome in the treatment of women with panhypopituitarism: a case report. J Reprod Med 61:78–82PubMedGoogle Scholar
  22. 22.
    Rajesh H, Yong YY, Zhu M, Chia D, Yu SL (2007) Growth hormone deficiency and supplementation at in vitro fertilisation. Singap Med J 48:514–518Google Scholar
  23. 23.
    Conway-Campbell BL, Wooh JW, Brooks AJ, Gordon D, Brown RJ, Lichanska AM, Chin HS, Barton CL, Boyle GM, Parsons PG, Jans DA, Waters MJ (2007) Nuclear targeting of the growth hormone receptor results in dysregulation of cell proliferation and tumorigenesis. Proc Natl Acad Sci USA 104:13331–13336CrossRefGoogle Scholar
  24. 24.
    Miwa I, Tamura H, Takasaki A, Yamagata Y, Shimamura K, Sugino N (2009) Pathophysiologic features of “thin” endometrium. Fertil Steril 91:998–1004CrossRefGoogle Scholar
  25. 25.
    Chien LW, Au HK, Chen PL, Xiao J, Tzeng CR (2002) Assessment of uterine receptivity by the endometrial-subendometrial blood flow distribution pattern in women undergoing in vitro fertilization-embryo transfer. Fertil Steril 78:245–251CrossRefGoogle Scholar
  26. 26.
    Ferrara N (2000) Vascular endothelial growth factor and the regulation of angiogenesis. Recent Prog Horm Res 55:15–35; discussion 35–16Google Scholar
  27. 27.
    Hannan NJ, Paiva P, Meehan KL, Rombauts LJ, Gardner DK, Salamonsen LA (2011) Analysis of fertility-related soluble mediators in human uterine fluid identifies VEGF as a key regulator of embryo implantation. Endocrinology 152:4948–4956CrossRefGoogle Scholar
  28. 28.
    Brunet-Dunand SE, Vouyovitch C, Araneda S, Pandey V, Vidal LJ, Print C, Mertani HC, Lobie PE, Perry JK (2009) Autocrine human growth hormone promotes tumor angiogenesis in mammary carcinoma. Endocrinology 150:1341–1352CrossRefGoogle Scholar
  29. 29.
    Potashnik G, Lunenfeld E, Shwartz I, Glezerman M, Roberts CT Jr, LeRoith D, Sharoni Y, Levy J (1995) Endogenous plasma growth hormone and the occurrence of pregnancies in patients undergoing in vitro fertilization and embryo transfer with ovarian stimulation. Hum Reprod 10:1065–1069CrossRefGoogle Scholar
  30. 30.
    Kaneko Y, Day ML, Murphy CR (2011) Integrin beta3 in rat blastocysts and epithelial cells is essential for implantation in vitro: studies with Ishikawa cells and small interfering RNA transfection. Hum Reprod 26:1665–1674CrossRefGoogle Scholar
  31. 31.
    Lessey BA, Castelbaum AJ (2002) Integrins and implantation in the human. Rev Endocr Metab Disord 3:107–117CrossRefGoogle Scholar
  32. 32.
    Tei C, Maruyama T, Kuji N, Miyazaki T, Mikami M, Yoshimura Y (2003) Reduced expression of alphavbeta3 integrin in the endometrium of unexplained infertility patients with recurrent IVF-ET failures: improvement by danazol treatment. J Assist Reprod Genet 20:13–20CrossRefGoogle Scholar
  33. 33.
    Altmae S, Mendoza-Tesarik R, Mendoza C, Mendoza N, Cucinelli F, Tesarik J (2018) Effect of growth hormone on uterine receptivity in women with repeated implantation failure in an oocyte donation program: a randomized controlled trial. J Endocr Soc 2:96–105CrossRefGoogle Scholar
  34. 34.
    Gleeson HK, Shalet SM (2005) GH responsiveness varies during the menstrual cycle. Eur J Endocrinol 153:775–779CrossRefGoogle Scholar
  35. 35.
    Lieberman SA, Mitchell AM, Marcus R, Hintz RL, Hoffman AR (1994) The insulin-like growth factor I generation test: resistance to growth hormone with aging and estrogen replacement therapy. Horm Metab Res 26:229–233CrossRefGoogle Scholar
  36. 36.
    Suikkari A, MacLachlan V, Koistinen R, Seppala M, Healy D (1996) Double-blind placebo controlled study: human biosynthetic growth hormone for assisted reproductive technology. Fertil Steril 65:800–805CrossRefGoogle Scholar
  37. 37.
    Xue-Mei W, Hong J, Wen-Xiang Z, Yang L (2016) The effects of growth hormone on clinical outcomes after frozen-thawed embryo transfer. Int J Gynaecol Obstet 133:347–350CrossRefGoogle Scholar
  38. 38.
    Chandrashekar V, Zaczek D, Bartke A (2004) The consequences of altered somatotropic system on reproduction. Biol Reprod 71:17–27CrossRefGoogle Scholar
  39. 39.
    Hull KL, Harvey S (2014) Growth hormone and reproduction: a review of endocrine and autocrine/paracrine interactions. Int J Endocrinol 2014:234014CrossRefGoogle Scholar
  40. 40.
    Thum T, Hoeber S, Froese S, Klink I, Stichtenoth DO, Galuppo P, Jakob M, Tsikas D, Anker SD, Poole-Wilson PA, Borlak J, Ertl G, Bauersachs J (2007) Age-dependent impairment of endothelial progenitor cells is corrected by growth-hormone-mediated increase of insulin-like growth-factor-1. Circ Res 100:434–443CrossRefGoogle Scholar
  41. 41.
    Moyano P, Rotwein P (2004) Mini-review: estrogen action in the uterus and insulin-like growth factor-I. Growth Horm IGF Res 14:431–435CrossRefGoogle Scholar
  42. 42.
    Boehm KD, Daimon M, Gorodeski IG, Sheean LA, Utian WH, Ilan J (1990) Expression of the insulin-like and platelet-derived growth factor genes in human uterine tissues. Mol Reprod Dev 27:93–101CrossRefGoogle Scholar
  43. 43.
    Kucuk T, Kozinoglu H, Kaba A (2008) Growth hormone co-treatment within a GnRH agonist long protocol in patients with poor ovarian response: a prospective, randomized, clinical trial. J Assist Reprod Genet 25:123–127CrossRefGoogle Scholar
  44. 44.
    Hartman ML, Xu R, Crowe BJ, Robison LL, Erfurth EM, Kleinberg DL, Zimmermann AG, Woodmansee WW, Cutler GB Jr, Chipman JJ, Melmed S, CCSAB International Hypo (2013) Prospective safety surveillance of GH-deficient adults: comparison of GH-treated vs. untreated patients. J Clin Endocrinol Metab 98:980–988CrossRefGoogle Scholar
  45. 45.
    Melmed S (2006) Medical progress: acromegaly. N Engl J Med 355:2558–2573CrossRefGoogle Scholar
  46. 46.
    Xu XQ, Emerald BS, Goh EL, Kannan N, Miller LD, Gluckman PD, Liu ET, Lobie PE (2005) Gene expression profiling to identify oncogenic determinants of autocrine human growth hormone in human mammary carcinoma. J Biol Chem 280:23987–24003CrossRefGoogle Scholar
  47. 47.
    Dreval AV IV, Trigolosova IV Misnikova, Kovalyova YA, Tishenina RS, Barsukov IA, Vinogradova AV, Wolffenbuttel BH (2014) Prevalence of diabetes mellitus in patients with acromegaly. Endocr Connect 3:93–98CrossRefGoogle Scholar
  48. 48.
    Fieffe S, Morange I, Petrossians P, Chanson P, Rohmer V, Cortet C, Borson-Chazot F, Brue T, Delemer B, French Acromegaly R (2011) Diabetes in acromegaly, prevalence, risk factors, and evolution: data from the French Acromegaly Registry. Eur J Endocrinol 164:877–884CrossRefGoogle Scholar
  49. 49.
    Bassiouny YA, Dakhly DMR, Bayoumi YA, Hashish NM (2016) Does the addition of growth hormone to the in vitro fertilization/intracytoplasmic sperm injection antagonist protocol improve outcomes in poor responders? A randomized, controlled trial. Fertil Steril 105:697–702CrossRefGoogle Scholar
  50. 50.
    Eftekhar M, Aflatoonian A, Mohammadian F, Eftekhar T (2013) Adjuvant growth hormone therapy in antagonist protocol in poor responders undergoing assisted reproductive technology. Arch Gynecol Obstet 287:1017–1021CrossRefGoogle Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 2018

Authors and Affiliations

  • N. Cui
    • 1
  • A.-M. Li
    • 1
  • Z.-Y. Luo
    • 1
  • Z.-M. Zhao
    • 1
  • Y.-M. Xu
    • 1
  • J. Zhang
    • 1
  • A.-M. Yang
    • 1
  • L.-L. Wang
    • 1
  • G.-M. Hao
    • 1
    Email author
  • B.-L. Gao
    • 2
    Email author
  1. 1.Department of Reproductive Medicine, The Second HospitalHebei Medical UniversityShijiazhuangPeople’s Republic of China
  2. 2.Department of Interventional TherapyHenan Provincial People’s HospitalZhengzhouPeople’s Republic of China

Personalised recommendations